MATERIALS AND METHODS
Clinical event rates (stroke/systemic embolism (SSE), myocardial infarction (MI), pulmonary embolism/deep vein thrombosis (PE/DVT), major bleeding events excluding hemorrhagic stroke (MBEHS), non-major bleeding events) among NVAF patients with CHADS 2 = 2 and C3 treated with individual OACs or warfarin were determined from the three OAC trials [5] [6] [7] ( Table 1) . Hemorrhagic stroke (HS) was considered as an efficacy and safety end point in the OAC vs. warfarin trials. To avoid costing twice, HS events were excluded from major bleeding events, but kept grouped with SSE. MBEHS rate was defined as the absolute event rate of major bleeding events minus HS. When the event rate for a particular clinical event was not reported in a clinical trial, the rate of an end point containing this clinical event was used [8] . The event rates of non-major bleeding events, including clinically relevant non-major bleeding events and other minor bleeding events, were not reported by stroke risk groups in the original clinical trial publications. In this analysis we assumed the relative risks of these non-major bleeding events for NVAF patients with different stroke risks to be the same as those for major bleeding events reported for each trial. These estimated relative risks of non-major bleeding events in combination with the absolute event rates of non-major bleeding events from the overall trial population were used to estimate the event rates of non-major bleeding events for the stroke risk groups. The event rates of the secondary end points, MI, and PE/DVT were assumed to be the same as those of the overall trial population since such stroke risk group-specific data were not reported in the OAC vs. warfarin clinical trials.
One-year incremental costs (US payer perspective) for clinical events were obtained and adjusted to 2010 costs [8, 9] . Based on the absolute risks for each of the clinical events, differences in medical costs associated with each OAC vs. warfarin were determined. Drug costs and monitoring expenses were not evaluated.
We additionally carried out a sensitivity Springer's policy concerning informed consent has been followed.
RESULTS
One-year medical costs of clinical events were as follows: SSE = $40,613 [10, 11] , MI = $37,446 [12] , PE/DVT = $19,532 [13] , MBEHS = $34,617 ARISTOTLE apixaban for the reduction in stroke and other thromboembolic events in atrial fibrillation, MBEHS major bleeding events excluding hemorrhagic stroke, MI myocardial infarction, NR not reported, NVAF nonvalvular atrial fibrillation, PE/DVT pulmonary embolism/deep vein thrombosis, RE-LY randomized evaluation of long-term anticoagulation therapy, ROCKET-AF rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation a Rates of MI and PE/DVT were not reported by CHADS 2 score and those from the overall trial population were used [8] b Relative risks of non-major bleeding events were assumed to be the same as major bleeding events in each trial, and these in combination with absolute event rates of non-major bleeding events from the overall trial populations were used for estimations of event rates
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[10], non-major bleeding event = $130 [8, 14] . In a year, overall medical cost differences associated with apixaban, dabigatran, and rivaroxaban use relative to warfarin among NVAF patients with CHADS 2 = 2 were estimated at -$298, -$143, and $117, respectively (negative numbers indicate cost reduction), and among those with CHADS 2 C 3 were estimated at -$697, $2, and -$100, respectively (Table 2 ).
In the sensitivity analysis, in which rates of clinical events for warfarin were estimated as weighted averages from the three OAC trials ARISTOTLE apixaban for the reduction in stroke and other thromboembolic events in atrial fibrillation, MBEHS major bleeding events excluding hemorrhagic stroke, MI myocardial infarction, NR not reported, NVAF nonvalvular atrial fibrillation, PE/DVT pulmonary embolism/deep vein thrombosis, RE-LY randomized evaluation of long-term anticoagulation therapy, ROCKET-AF rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation Table 3 Sensitivity analysis: estimated differences in medical costs for clinical events among NVAF patients at moderate and high stroke risk
Non-major bleeding events
ARISTOTLE apixaban for the reduction in stroke and other thromboembolic events in atrial fibrillation, MBEHS major bleeding events excluding hemorrhagic stroke, MI myocardial infarction, NR not reported, NVAF nonvalvular atrial fibrillation, PE/DVT pulmonary embolism/deep vein thrombosis, RE-LY randomized evaluation of long-term anticoagulation therapy, ROCKET-AF rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation and those of individual OACs as relative risks to the common warfarin event rates, overall medical cost differences associated with apixaban, dabigatran, and rivaroxaban use relative to warfarin among NVAF patients with CHADS 2 = 2 were estimated at -$332, -$151, and $135, respectively, and among those with CHADS 2 C 3 were estimated at -$664, $0, and -$63, respectively (Table 3) .
DISCUSSION
Differences in medical costs for OACs compared with warfarin are dependent on the specific OAC used and stroke risk. In this analysis, only apixaban use was associated with consistently reduced medical costs relative to warfarin for NVAF patients with moderate or high stroke risk. The primary drivers for medical cost reductions associated with apixaban use, relative to warfarin, were reduced rates of SSE, which were 14% and 32% lower, and MBEHS, which were 20% and 25% lower, for NVAF patients with CHADS 2 = 2 and CHADS 2 C 3, respectively. The use of either dabigatran or rivaroxaban instead of warfarin was associated with lower risks for SSE, but not consistently lower risks for other clinical events and, therefore, their cost differences were less.
This analysis was based on clinical trial data and the application of the results to routine clinical practice requires further assessment. Since the occurrences of stroke and major bleeding events may be greater in routine clinical practice [15] , the cost differences may have been underestimated. Additionally, when major bleeding events and HS relative rates were originally reported as hazard ratios, the analysis measured the relative risk of ''time to first event'' [5] [6] [7] . The subtraction approach used in this analysis did not consider any impact of timing and, thus, may have underestimated the rate of MBEHS. Springer's policy concerning informed consent has been followed.
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